The finding that multiple cancers lack one of two NMTs, while stromal and normal tissues do not, enables the treatment of NMT2-deficient cancer cells with an NMT inhibitor. It is shown herein that NMT2 expression is reduced or eliminated in certain cancers, and in one example lymphomas, via an epigenetic mechanism(s). Reduction or elimination of NMT2 expression renders the cancer sensitive inhibitors of NMT.
